Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

332
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
332
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

323
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
323
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

312
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
312
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

283
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
283
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.2K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.2K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

3.7K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision by recognition: smarter firing for better lithotripsy.

BJU international·2026
Same author

Structured template for standardised reporting of non-contrast computed tomography in urinary stone disease as a superior tool for urologists - a randomised controlled trial.

BMC urology·2026
Same author

Feasibility and safety of robot-assisted radical prostatectomy following laser enucleation of the prostate.

Central European journal of urology·2026
Same author

Evaluation of the Transition from Holmium:YAG to Pulsed Thulium:YAG for Laser Endoscopic Enucleation of the Prostate and the Effect on Procedural Performance.

European urology open science·2026
Same author

WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms.

European urology focus·2026
Same author

Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy.

Molecules (Basel, Switzerland)·2025
Same journal

The Prevalence of Hospitalized Cases of Necrotizing Fasciitis: Anatomical Distribution, Amputations, and In-Hospital Mortality, 2019-2024.

Deutsches Arzteblatt international·2026
Same journal

Subclinical Atrial Fibrillation: Detection, Stroke Risk, and Treatment.

Deutsches Arzteblatt international·2026
Same journal

Fewer Premature Births After Assisted Reproduction.

Deutsches Arzteblatt international·2026
Same journal

Femoral Artery Pseudoaneurysm Due to Stent Fracture in PAOD.

Deutsches Arzteblatt international·2026
Same journal

Pain-Adapted Full Weight-bearing After Ankle Fracture Surgery: A Multicenter, Pragmatic, Single-armed Prospective Study.

Deutsches Arzteblatt international·2026
Same journal

Popliteal Artery Entrapment Syndrome.

Deutsches Arzteblatt international·2026
See all related articles

Related Experiment Video

Updated: Nov 17, 2025

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.3K

Current Treatment for Benign Prostatic Hyperplasia.

Arkadiusz Miernik1, Christian Gratzke

  • 1Department of Urology at University Hospital Freiburg.

Deutsches Arzteblatt International
|February 17, 2021
PubMed
Summary
This summary is machine-generated.

Benign prostatic hyperplasia (BPH) management involves complex pharmacological and surgical options. While transurethral resection of the prostate (TURP) is standard, newer techniques offer alternatives, but require further study.

More Related Videos

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.5K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.6K

Related Experiment Videos

Last Updated: Nov 17, 2025

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.3K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.5K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.6K

Area of Science:

  • Urology
  • Geriatrics

Background:

  • Benign prostatic hyperplasia (BPH) affects most men over 60.
  • BPH causes urinary storage and emptying disorders.

Purpose of the Study:

  • To review current management strategies for BPH.
  • To assess the efficacy and safety of various BPH treatments.

Main Methods:

  • Selective literature search.
  • Scrutiny of guidelines and meta-analyses.

Main Results:

  • BPH management is complex, with pharmacological and surgical options.
  • Transurethral resection of the prostate (TURP) is the traditional standard.
  • Transurethral enucleation offers a better risk profile and is displacing other procedures.
  • Innovative treatments exist but require long-term data.

Conclusions:

  • Interdisciplinary care is essential for BPH patients.
  • Efficacy and safety of new treatments need randomized trial validation.